The kidney in congestive heart failure: Renal adverse event rate of treatment

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 1, 2001, Pages 99-107

  Delles, Christian ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Adverse events; Angiotensin converting enzyme inhibitors; Congestive heart failure; Renal function

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; RAMIPRIL; TRANDOLAPRIL; VASOPEPTIDASE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HUMAN; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY PERFUSION; NEPHROTOXICITY; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS;

EID: 0034932429     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200107000-00011     Document Type: Article

References (73)

1. Prevalence and mortality of congestive heart failure in the United States
2. Effects of enalapril on mortality in severe congestive heart failure
3. Survival after the onset of congestive heart failure in Framingham Heart Study subjects
4. The prognostic implication of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction
5. Renal function, neurohormonal activation, and survival in patients with chronic heart failure
6. Renal disorders and heart disease
7. Color Doppler ultrasonography for the assessment of renal blood flow in heart failure
8. Guidelines for the evaluation and management of heart failure
9. The management of chronic heart failure
10. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
11. ACE inhibitors and the kidney
12. Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril
13. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
14. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
15. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
16. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
17. Risk of morbidity from renovascular disease in elderly patients with congestive heart failure
18. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease
19. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
20. Nephroprotection by antihypertensive therapy
21. Renal-artery stenosis
22. Klinischer einsatz der ACE-Hemmer. Überblick für die Praxis
23. Long- versus short-term effects of two different ACE inhibitors on renal haemodynamics: Preliminary results from an ongoing trial
24. First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: A double-blind, randomized, multicenter study
25. Comparison of captopril and enalapril in patients with severe chronic heart failure
26. Trough: Peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors
27. Effects of captopril and enalapril on renal function in elderly patients with congestive heart failure
28. Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure: A comparison between a short- and a long-acting angiotensin-converting enzyme inhibitor
29. Angiotensin-converting enzyme inhibitors in the clinical setting of chronic congestive heart failure
30. The effect of prescribed daily dose frequency on patient medication compliance
31. Compliance and the elderly hypertensive
32. Short- and long-acting angiotensin-converting enzyme inhibitors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failure
33. Infarct-related heart failure: The choice of ACE inhibitor does not matter
34. Das renin-angiotensin-system bei kardiovaskulären erkrankungen
35. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
36. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Trial Survival Study ELITE II
37. Improving outcomes in congestive heart failure: Val-HeFT
38. Beta-blockers and renal function
39. Proximal tubular function in essential hypertensives on beta-blocker therapy with atenolol
40. Impact of α- versus β-blockers on hypertensive target organ damage: Results of a double-blind, randomized, controlled clinical trial
41. Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients
42. Effect of amlodipine on morbidity and mortality in severe chronic heart failure
43. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril
44. The natriuretic effect of nifedipine gastrointestinal therapeutic system remains despite the presence of mild-to-moderate renal failure
45. The effects of isradipine and spirapril as monotherapy and combined therapy on blood pressure, renal hemodynamics, natriuresis, and urinary kallikrein in hypertensive nephropathy
46. Natriuretic effect of nitrendipine is preceded by systemic and renal hemodynamic effects
47. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
48. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES])
49. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
50. Bi-ventricular pacing in congestive heart failure: Current experience and future directions
51. The Multicenter Study of Enhanced External Counterpulsation (MUST-EECP): Effect of EECP on exercise-induced myocardial ischemia and anginal episodes
52. Plasma norepinephrine, plasma renin activity, and congestive heart failure
53. Influence of intrarenally generated angiotensin II on renal hemodynamics and tubular absorption
54. Angiotensin II: A powerful controller of sodium transport in the early proximal tubule
55. Control of renal potassium excretion
56. Pathophysiology of heart failure
57. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
58. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity
59. Effects of renal nerves and neurotransmitters on renal function
60. Neural control of renal function
61. Natriuretic peptides
62. Evidence for endothelin-1-mediated vasoconstriction in severe heart failure
63. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
64. Plasma endothelin in congestive heart failure: A predictor of cardiac death?
65. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension
66. Renal actions of endothelin-1 and endothelin-3: Interactions with the prostaglandin system and nitric oxide
67. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
68. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
69. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)
70. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
71. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
72. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
73. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure